203 related articles for article (PubMed ID: 35569509)
1. Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression.
Beauvais DM; Nelson SE; Adams KM; Stueven NA; Jung O; Rapraeger AC
J Biol Chem; 2022 Jun; 298(6):102029. PubMed ID: 35569509
[TBL] [Abstract][Full Text] [Related]
2. Syndecan-1 and Syndecan-4 Capture Epidermal Growth Factor Receptor Family Members and the α3β1 Integrin Via Binding Sites in Their Ectodomains: NOVEL SYNSTATINS PREVENT KINASE CAPTURE AND INHIBIT α6β4-INTEGRIN-DEPENDENT EPITHELIAL CELL MOTILITY.
Wang H; Jin H; Rapraeger AC
J Biol Chem; 2015 Oct; 290(43):26103-13. PubMed ID: 26350464
[TBL] [Abstract][Full Text] [Related]
3. Cytoplasmic domain interactions of syndecan-1 and syndecan-4 with α6β4 integrin mediate human epidermal growth factor receptor (HER1 and HER2)-dependent motility and survival.
Wang H; Jin H; Beauvais DM; Rapraeger AC
J Biol Chem; 2014 Oct; 289(44):30318-30332. PubMed ID: 25202019
[TBL] [Abstract][Full Text] [Related]
4. Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells.
Thangasamy A; Rogge J; Ammanamanchi S
J Biol Chem; 2009 May; 284(21):14001-10. PubMed ID: 19307182
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for the binding specificity of human Recepteur d'Origine Nantais (RON) receptor tyrosine kinase to macrophage-stimulating protein.
Chao KL; Gorlatova NV; Eisenstein E; Herzberg O
J Biol Chem; 2014 Oct; 289(43):29948-60. PubMed ID: 25193665
[TBL] [Abstract][Full Text] [Related]
6. Interaction of syndecan and alpha6beta4 integrin cytoplasmic domains: regulation of ErbB2-mediated integrin activation.
Wang H; Leavitt L; Ramaswamy R; Rapraeger AC
J Biol Chem; 2010 Apr; 285(18):13569-79. PubMed ID: 20181947
[TBL] [Abstract][Full Text] [Related]
7. Involvement of recepteur d'origine nantais receptor tyrosine kinase in Epstein-Barr virus-associated nasopharyngeal carcinoma and its metastasis.
Chou YC; Chen CL; Yeh TH; Lin SJ; Chen MR; Doong SL; Lu J; Tsai CH
Am J Pathol; 2012 Nov; 181(5):1773-81. PubMed ID: 22974584
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
[TBL] [Abstract][Full Text] [Related]
9. The MSP-RON axis stimulates cancer cell growth in models of triple negative breast cancer.
Millar R; Kilbey A; Remak SJ; Severson TM; Dhayade S; Sandilands E; Foster K; Bryant DM; Blyth K; Coffelt SB
Mol Oncol; 2020 Aug; 14(8):1868-1880. PubMed ID: 32484599
[TBL] [Abstract][Full Text] [Related]
10. Integrin-mediated RON growth factor receptor phosphorylation requires tyrosine kinase activity of both the receptor and c-Src.
Danilkovitch-Miagkova A; Angeloni D; Skeel A; Donley S; Lerman M; Leonard EJ
J Biol Chem; 2000 May; 275(20):14783-6. PubMed ID: 10747844
[TBL] [Abstract][Full Text] [Related]
11. Recepteur d'origine nantais contributes to the development of endometriosis via promoting epithelial-mesenchymal transition of a endometrial epithelial cells.
Yu Q; Wang J; Li T; Guo X; Ding S; Che X; Zhu L; Peng Y; Xu X; Zou G; Zhang X
J Cell Mol Med; 2021 Feb; 25(3):1601-1612. PubMed ID: 33410267
[TBL] [Abstract][Full Text] [Related]
12. The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer.
Zhao H; Chen MS; Lo YH; Waltz SE; Wang J; Ho PC; Vasiliauskas J; Plattner R; Wang YL; Wang SC
Oncogene; 2014 Mar; 33(11):1429-37. PubMed ID: 23542172
[TBL] [Abstract][Full Text] [Related]
13. RON (recepteur d'origine nantais) expression and its association with tumor progression in laryngeal squamous cell carcinoma.
Kim SA; Yoon TM; Lee DH; Park YL; Lee KH; Lim SC; Joo YE; Lee JK
Auris Nasus Larynx; 2014 Apr; 41(2):201-6. PubMed ID: 24287326
[TBL] [Abstract][Full Text] [Related]
14. RON, a tyrosine kinase receptor involved in tumor progression and metastasis.
Camp ER; Liu W; Fan F; Yang A; Somcio R; Ellis LM
Ann Surg Oncol; 2005 Apr; 12(4):273-81. PubMed ID: 15827676
[TBL] [Abstract][Full Text] [Related]
15. Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor.
Peace BE; Hill KJ; Degen SJ; Waltz SE
Exp Cell Res; 2003 Oct; 289(2):317-25. PubMed ID: 14499632
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.
Chao KL; Tsai IW; Chen C; Herzberg O
PLoS One; 2012; 7(7):e41912. PubMed ID: 22848655
[TBL] [Abstract][Full Text] [Related]
17. Macrophage stimulating protein preserves blood brain barrier integrity after intracerebral hemorrhage through recepteur d'origine nantais dependent GAB1/Src/β-catenin pathway activation in a mouse model.
Lu T; Wang Z; Prativa S; Xu Y; Wang T; Zhang Y; Yu L; Xu N; Tang J; You W; Chen G; Zhang JH
J Neurochem; 2019 Jan; 148(1):114-126. PubMed ID: 30380151
[TBL] [Abstract][Full Text] [Related]
18. Ron tyrosine kinase receptor synergises with EGFR to confer adverse features in head and neck squamous cell carcinoma.
Keller J; Nimnual AS; Shroyer KR; Joy C; Ischenko I; Chandler CS; Dong LM; Hayman MJ; Chan EL
Br J Cancer; 2013 Jul; 109(2):482-92. PubMed ID: 23799848
[TBL] [Abstract][Full Text] [Related]
19. Small interfering RNA-directed targeting of RON alters invasive and oncogenic phenotypes of human hepatocellular carcinoma cells.
Cho SB; Park YL; Song YA; Kim KY; Lee GH; Cho DH; Myung DS; Park KJ; Lee WS; Chung IJ; Choi SK; Kim KK; Joo YE
Oncol Rep; 2011 Dec; 26(6):1581-6. PubMed ID: 21874262
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase.
Wang MH; Wang D; Chen YQ
Carcinogenesis; 2003 Aug; 24(8):1291-300. PubMed ID: 12807733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
